These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22004229)

  • 1. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial.
    Gopinath K; Danda D
    Int J Rheum Dis; 2011 Oct; 14(4):332-9. PubMed ID: 22004229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
    Lee EY; Lee EB; Park BJ; Lee CK; Yoo B; Lim MK; Shim SC; Sheen DH; Seo YI; Kim HA; Baek HJ; Song YW
    Clin Ther; 2006 Dec; 28(12):2052-60. PubMed ID: 17296461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P; Esselens G; Westhovens R
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 1,25 dihydroxy vitamin D3 supplementation on pain relief in early rheumatoid arthritis.
    Mukherjee D; Lahiry S; Thakur S; Chakraborty DS
    J Family Med Prim Care; 2019 Feb; 8(2):517-522. PubMed ID: 30984665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of conjugated linoleic acids, vitamin E and their combination on the clinical outcome of Iranian adults with active rheumatoid arthritis.
    Aryaeian N; Shahram F; Djalali M; Eshragian MR; Djazayeri A; Sarrafnejad A; Salimzadeh A; Naderi N; Maryam C
    Int J Rheum Dis; 2009 Apr; 12(1):20-8. PubMed ID: 20374312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study.
    Di Franco M; Barchetta I; Iannuccelli C; Gerardi MC; Frisenda S; Ceccarelli F; Valesini G; Cavallo MG
    BMC Musculoskelet Disord; 2015 Mar; 16():53. PubMed ID: 25887374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time?
    Plant MJ; O'Sullivan MM; Lewis PA; Camilleri JP; Coles EC; Jessop JD
    Rheumatology (Oxford); 2005 Sep; 44(9):1181-5. PubMed ID: 15972357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
    Nell VP; Machold KP; Eberl G; Stamm TA; Uffmann M; Smolen JS
    Rheumatology (Oxford); 2004 Jul; 43(7):906-14. PubMed ID: 15113999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
    Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
    J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
    Homer D; Nightingale P; Jobanputra P
    Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.